Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients.

Willder, J M; Heng, S J; McCall, P; Adams, C E; Tannahill, C; Fyffe, G; Seywright, M; Horgan, P G; Leung, H Y; Underwood, M A; Edwards, J

Willder, J M; Heng, S J; McCall, P; Adams, C E; Tannahill, C; Fyffe, G; Seywright, M; Horgan, P G; Leung, H Y; Underwood, M A; Edwards, J.

Affiliation

Willder JM; Institute of Cancer, University of Glasgow, McGregor Building, Western Infirmary, Glasgow G11 6NT, UK.

Br J Cancer ; 108(1): 139-48, 2013 Jan 15.

Article in En | MEDLINE | ID: mdl-23321516

Subject(s)

MAP Kinase Signaling System/physiology; Prostatic Neoplasms/metabolism; Purines/pharmacokinetics; Receptors, Androgen/metabolism; Aged; Biomarkers, Tumor/antagonists & inhibitors; CDC2 Protein Kinase/antagonists & inhibitors; CDC2 Protein Kinase/metabolism; Disease-Free Survival; Humans; Male; Phosphorylation; Prognosis; Prostate-Specific Antigen/metabolism; Recurrence; Roscovitine; Serine/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Purines / Receptors, Androgen / MAP Kinase Signaling System Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male Language: En Journal: Br J Cancer Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google